Suppr超能文献

一种用于叔胺的新型前药方法。3. 两种N-磷酰氧基甲基前药在大鼠和犬体内的评价

A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs.

作者信息

Krise J P, Charman W N, Charman S A, Stella V J

机构信息

Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Avenue, Lawrence, Kansas 66047, USA.

出版信息

J Pharm Sci. 1999 Sep;88(9):928-32. doi: 10.1021/js980382v.

Abstract

N-phosphonooxymethyl derivatives of tertiary amine containing drugs have been identified as a novel prodrug approach for improving aqueous solubility. The in vivo reversion of two prodrugs to the corresponding parent compounds following iv and im administration to rats and dogs was investigated. Equimolar doses of parent drugs (loxapine or cinnarizine) and the corresponding prodrugs were each administered via a rapid iv infusion to rats and dogs. Equimolar doses of loxapine and its prodrug were each administered im to rats only. Blood samples were collected over 12 h, and plasma was assayed for both parent drug and intact prodrug by HPLC. Comparison of the plasma AUC for the parent drugs following administration of the parent drugs and prodrugs allowed estimation of the apparent bioavailability of parent drug from prodrug dosing. Plasma levels of the prodrugs fell below the limit of detection 5 min after iv infusion with an approximate half-life of 1 min. The mean AUCs following iv and im dosing of parent drugs were not statistically different from the parent drug AUCs obtained after prodrug dosing. The results are consistent with rapid and quantitative prodrug to parent drug reversion following administration of the phosphonooxymethyl prodrugs to the rats and dogs. This information, together with previous studies on the synthesis and physicochemical evaluation of the prodrugs, suggests that this novel prodrug strategy is a very promising approach for overcoming solubility limitations seen with many tertiary amine containing drugs at physiological pH values.

摘要

含叔胺药物的N-膦酰氧基甲基衍生物已被确定为一种提高水溶性的新型前药方法。研究了两种前药在大鼠和犬体内静脉注射和肌肉注射后向相应母体化合物的体内转化情况。将等摩尔剂量的母体药物(洛沙平或桂利嗪)和相应的前药分别通过快速静脉输注给予大鼠和犬。仅将等摩尔剂量的洛沙平和其前药分别肌肉注射给大鼠。在12小时内采集血样,通过高效液相色谱法测定血浆中的母体药物和完整前药。比较母体药物和前药给药后母体药物的血浆曲线下面积(AUC),可以估算前药给药后母体药物的表观生物利用度。静脉输注后5分钟,前药的血浆水平降至检测限以下,半衰期约为1分钟。母体药物静脉注射和肌肉注射给药后的平均AUC与前药给药后获得的母体药物AUC在统计学上无差异。结果表明,将膦酰氧基甲基前药给予大鼠和犬后,前药能快速且定量地转化为母体药物。这些信息,连同之前关于前药合成和理化性质评估的研究,表明这种新型前药策略是克服许多含叔胺药物在生理pH值下溶解度限制的非常有前景的方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验